Formulation: A crystalline solid
Formal Name: (2E)-3-[2,6-dichloro-4-[[[4-[3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-2-propenoic acid
Purity: ≥98%
Formula Markup: C29H32Cl2N2O5S
Formula Weight: 591,5
Shelf life (days): 1460
CAS Number: 1110766-97-6
Notes: Lusutrombopag is an agonist of the thrombopoietin receptor.{45125} It induces proliferation of Ba/F3 cells expressing human MPL, the gene for the thrombopoietin receptor, with an EC50 value of 84 nM but not of those expressing mouse Mpl.{45126} Lusutrombopag (0.3-10 mg/kg per day) increases the number of circulating platelets in a transgenic mouse model expressing human MPL and increases the number of megakaryocytes in the bone marrow when administered at a dose of 10 mg/kg per day. Formulations containing lusutrombopag have been used in the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo invasive procedures.